Brief: Atossa Completes Enrollment Of 80Mg Pharmacokinetic Run-In Cohort In Phase 2 Evangeline Clinical Trial
22/07/2024 13:39
July 22 (Reuters) - Atossa Therapeutics Inc ATOS.O :
* ATOSSA THERAPEUTICS COMPLETES ENROLLMENT OF 80MG
PHARMACOKINETIC
RUN-IN COHORT IN PHASE 2 EVANGELINE CLINICAL TRIAL EVALUATING
(Z)-ENDOXIFEN AS A NEOADJUVANT TREATMENT FOR ER+ / HER2- BREAST
CANCER
Source text for Eikon: ID:nGNX2pn2yT
Further company coverage: ATOS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary